Home » Archive by Category


First Surgical Implant of ZIP ULTRA(TM) MIS Interspinous Device Performed in Israel

October 31, 2014 – 6:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Oct. 31, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first surgical implant of the company’s ZIP ULTRAT Minimally Invasive interspinous device in Israel. Multiple surgeries have now been performed at the Herzliya Medical Center by Prof. Reuven Gepstein.

Research Scientist (Carlsbad, CA)

October 31, 2014 – 5:51 am | Edit Post

Essential Functions and Responsibilities:
As Principal Investigator and in collaboration with others, initiate, design, develop, execute and implement scientific research projects that are critical to company strategies and image.
Investigate feasi [...]

NuVasive, Inc. Reports Third Quarter 2014 Financial Results And Increases Full Year Guidance

October 31, 2014 – 5:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – Oct 30, 2014) – NuVasive, Inc. (NASDAQ: NUVA) NuVasive, Inc. (NASDAQ: NUVA) (“NuVasive” or the “Company”), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, today announced financial results for the quarter ended September 30, 2014.”We are pleased to report results for the third…

Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures

October 31, 2014 – 5:00 am | Edit Post

SAN FRANCISCO, Oct. 31, 2014 /PRNewswire/ — Imago BioSciences, Inc., a biotech company developing innovative therapeutics, today announced a $26.5 million Series A financing led by Clarus Ventures LLC, a global investment firm founded by a team of accomplished investment and operating professionals dedicated to life sciences.  Other investors participating in the round include Frazier Healthcare, Amgen Ventures, and Merck Research Labs Venture Fund.  Representatives from Clarus Ventures and Frazier Healthcare will join the company’s board of directors.

“Imago BioSciences is extremely gratified with the makeup of this investment syndicate,” said Hugh Young Rienhoff, M.D., CEO at Imago BioSciences.  “They comprise a group of experienced financial and strategic investors who provide financial support to progress our clinical development program in a direction important to patients and their physicians.”

Proceeds from the financing will be used to advance the research and clinical development program of therapeutics that alter gene expression patterns.  The company’s clinical focus is on orphan diseases that involve genetic alterations disturbing normal patterns of gene expression, or diseases in which modifying gene expression patterns can have a therapeutic effect.

About Imago BioSciences

Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians.  The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases.  Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.  More information is available at www.imagobio.com.
SOURCE Imago BioSciences

Zogenix, Inc. And Purdue Pharma L.P. Exchange Waivers Of Regulatory Exclusivity For Extended-Release Hydrocodone Products

October 31, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 31, 2014 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P. (Purdue) under…

Regulus Therapeutics, Inc. Announces Timing For Third Quarter 2014 Financial Results Webcast And Conference Call

October 31, 2014 – 5:00 am | Edit Post

LA JOLLA, Calif., Oct. 30, 2014 /PRNewswire/ –Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report…

Alphatec Holdings, Inc. Announces Third Quarter 2014 Revenue And Financial Results

October 31, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today financial results for the third quarter ended September 30, 2014.Third quarter consolidated net revenues of $51.0 million.

Eisai Inc. Relase: Lorcaserin Data To Be Presented At The s Annual Scientific Meeting

October 31, 2014 – 5:00 am | Edit Post

WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 31,2014 /PRNewswire/ –Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the American Society for Metabolic…

Webcast Alert: Isis Pharmaceuticals, Inc.’ Third Quarter 2014 Financial Results Conference Call

October 31, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Oct. 31, 2014 /PRNewswire/ –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

Vital Therapies, Inc. (VTI) Announces Third Quarter 2014 Financial Results Conference Call With Webcast And Upcoming Conference Presentation

October 31, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) — Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting treatment of acute liver failure, will release its third quarter 2014 financial results after the market closes on Thursday, November 13, 2014. The…